Lucid Diagnostics Stock Performance
| LUCD Stock | USD 1.21 0.04 3.20% |
Lucid Diagnostics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.06, which conveys a somewhat significant risk relative to the market. Lucid Diagnostics returns are very sensitive to returns on the market. As the market goes up or down, Lucid Diagnostics is expected to follow. Lucid Diagnostics right now secures a risk of 2.72%. Please verify Lucid Diagnostics maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to decide if Lucid Diagnostics will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lucid Diagnostics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound fundamental indicators, Lucid Diagnostics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
1 | Lucid targets industry-first self-driving car technology with Nvidia | 10/28/2025 |
2 | Lucid Diagnostics signals imminent Medicare coverage for EsoGuard while strengthening commercial payer engagement | 11/12/2025 |
3 | Is Lucid Diagnostics Inc. stock oversold or undervalued - Market Growth Report Pattern Based Trade Signal System - newser.com | 11/18/2025 |
4 | Lucid Diagnostics files for 175 mln mixed securities shelf offering - MSN | 12/08/2025 |
5 | Heres Why Lucid Diagnostics Declined in Q3 | 12/24/2025 |
6 | Disposition of tradable shares by Aklog Lishan of Lucid Diagnostics subject to Rule 16b-3 | 01/02/2026 |
7 | Lucid Diagnostics Insider Ups Holding By 162 percent During Year | 01/09/2026 |
| Begin Period Cash Flow | 18.9 M | |
| Total Cashflows From Investing Activities | -646 K | |
| Free Cash Flow | -44.8 M |
Lucid Diagnostics Relative Risk vs. Return Landscape
If you would invest 121.00 in Lucid Diagnostics on October 21, 2025 and sell it today you would earn a total of 0.00 from holding Lucid Diagnostics or generate 0.0% return on investment over 90 days. Lucid Diagnostics is currently generating 0.0365% in daily expected returns and assumes 2.72% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Lucid, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lucid Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lucid Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lucid Diagnostics, and traders can use it to determine the average amount a Lucid Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0134
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LUCD |
Based on monthly moving average Lucid Diagnostics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lucid Diagnostics by adding it to a well-diversified portfolio.
Lucid Diagnostics Fundamentals Growth
Lucid Stock prices reflect investors' perceptions of the future prospects and financial health of Lucid Diagnostics, and Lucid Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lucid Stock performance.
| Return On Equity | -3.31 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (9.71) % | ||||
| Current Valuation | 189.91 M | ||||
| Shares Outstanding | 131.1 M | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 36.06 X | ||||
| Revenue | 4.35 M | ||||
| Gross Profit | (2.56 M) | ||||
| EBITDA | (44.34 M) | ||||
| Net Income | (45.53 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 21.25 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (44.14 M) | ||||
| Earnings Per Share | (0.77) X | ||||
| Market Capitalization | 158.63 M | ||||
| Total Asset | 30.71 M | ||||
| Retained Earnings | (203.77 M) | ||||
| Working Capital | 1.62 M | ||||
About Lucid Diagnostics Performance
By analyzing Lucid Diagnostics' fundamental ratios, stakeholders can gain valuable insights into Lucid Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lucid Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lucid Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 17.32 | 16.45 | |
| Return On Tangible Assets | (1.37) | (1.44) | |
| Return On Capital Employed | (5.76) | (5.48) | |
| Return On Assets | (1.33) | (1.40) | |
| Return On Equity | (7.60) | (7.22) |
Things to note about Lucid Diagnostics performance evaluation
Checking the ongoing alerts about Lucid Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lucid Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lucid Diagnostics may become a speculative penny stock | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.35 M. Net Loss for the year was (45.53 M) with loss before overhead, payroll, taxes, and interest of (2.56 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (44.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Lucid Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Lucid Diagnostics Insider Ups Holding By 162 percent During Year |
- Analyzing Lucid Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lucid Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Lucid Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lucid Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lucid Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lucid Diagnostics' stock. These opinions can provide insight into Lucid Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |